Open in Screener

ANAB

AnaptysBio Inc

Apr 01 • 04:00PM ET

56.73

+1.27 2.29 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX BMRN ALNY IONS SRPT EXEL BLUE INCY RGEN

| Held by: VTI XBI IWM VXF IBB IWO SCHA VTWO IWC FFTY

Index	RUT	P/E	-	EPS (ttm)	-0.52	Insider Own	6.87%	Shs Outstand	28.02M	Perf Week	-13.24%
Market Cap	1.63B	Forward P/E	-	EPS next Y	-3.25	Insider Trans	-8.97%	Shs Float	26.77M	Perf Month	7.38%
Enterprise Value	1.61B	PEG	-	EPS next Q	-0.96	Inst Own	98.77%	Short Float	17.91%	Perf Quarter	17.62%
Income	-13.23M	P/S	6.95	EPS this Y	-757.32%	Inst Trans	-5.60%	Short Ratio	8.80	Perf Half Y	85.27%
Sales	234.60M	P/B	42.72	EPS next Y	17.47%	ROA	-3.12%	Short Interest	4.79M	Perf YTD	17.02%
Book/sh	1.33	P/C	5.23	EPS next 5Y	-3.89%	ROE	-24.49%	52W High	68.39 -17.05%	Perf Year	208.32%
Cash/sh	10.84	P/FCF	83.17	EPS past 3/5Y	53.48% 8.82%	ROIC	-4.06%	52W Low	15.40 268.38%	Perf 3Y	160.71%
Dividend Est.	-	EV/EBITDA	31.99	Sales past 3/5Y	183.58% 25.62%	Gross Margin	98.97%	Volatility	9.72% 7.74%	Perf 5Y	160.35%
Dividend TTM	-	EV/Sales	6.86	EPS Y/Y TTM	94.31%	Oper. Margin	20.42%	ATR (14)	4.20	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.07	Sales Y/Y TTM	157.01%	Profit Margin	-5.64%	RSI (14)	44.62	Recom	1.27
Dividend Gr. 3/5Y	- -	Current Ratio	9.07	EPS Q/Q	321.26%	SMA20	-7.95%	Beta	0.41	Target Price	81.00
Payout	-	Debt/Eq	7.81	Sales Q/Q	151.08%	SMA50	1.76%	Rel Volume	2.22	Prev Close	55.46
Employees	104	LT Debt/Eq	7.75	Earnings	Mar 03 AMC	SMA200	50.60%	Avg Volume	544.94K	Price	56.73
IPO	Jan 26, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	83.12% 24.37%	Trades		Volume	1,209,082	Change	2.29%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Resumed	UBS	Buy	$70
Oct-13-25	Initiated	Barclays	Overweight	$78
Jun-04-25	Upgrade	H.C. Wainwright	Neutral → Buy	$38
Feb-04-25	Initiated	Wolfe Research	Outperform	$25
Dec-11-24	Downgrade	H.C. Wainwright	Buy → Neutral	$52 → $19
Dec-02-24	Downgrade	BTIG Research	Buy → Neutral
Jul-22-24	Initiated	H.C. Wainwright	Buy	$55
Jul-19-24	Upgrade	JP Morgan	Neutral → Overweight	$29 → $69
Apr-16-24	Initiated	Leerink Partners	Outperform	$47
Apr-11-24	Initiated	Wells Fargo	Overweight	$56
Mar-12-24	Upgrade	Wedbush	Neutral → Outperform	$20 → $34
Feb-26-24	Initiated	BTIG Research	Buy	$55
Feb-21-24	Initiated	Stifel	Buy	$50
Feb-16-24	Initiated	Piper Sandler	Overweight	$80
May-22-23	Upgrade	JP Morgan	Underweight → Neutral	$31 → $30
May-18-23	Initiated	TD Cowen	Outperform
Jan-06-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-01-22	Upgrade	Guggenheim	Neutral → Buy	$44
Sep-19-22	Resumed	H.C. Wainwright	Buy	$35
Sep-13-22	Downgrade	Truist	Buy → Hold	$50 → $28

Show Previous Ratings

Mar-27-26 09:00AM	First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement (GlobeNewswire) -11.68%
09:00AM	Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics (GlobeNewswire)
09:00AM	Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update (GlobeNewswire)
Mar-04-26 12:47PM	AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference (MarketBeat) +14.61%
Mar-03-26 05:35PM	AnaptysBio, Inc. (ANAB) Q4 Earnings and Revenues Top Estimates (Zacks)
04:15PM	Loading…
04:15PM	Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-12-26 03:08PM	AnaptysBio Details Q2 Royalty Spin, Jemperli Growth and ANB033 Celiac Data Coming in Q4 (MarketBeat)
Feb-11-26 04:05PM	AnaptysBio Teases Q2 Split Into RoyaltyCo and Biopharma Spin, Flags Jemperli and Pipeline Catalysts (MarketBeat) +9.97%
Feb-05-26 04:15PM	Anaptys Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Feb-03-26 01:57PM	Biotech Leader Eyes Spin-Off Amid Massive Sales Surge (Investor's Business Daily)
Jan-13-26 11:02PM	AnaptysBio Teases 2026 Split, JEMPERLI Royalty Upside and Key Clinical Catalysts at JPM Conf (MarketBeat)
Jan-09-26 01:56PM	AnaptysBio Pushes Back Against Lawsuit Over Cancer Drug Jemperli Royalties (Benzinga)
Jan-08-26 06:00PM	Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary (GlobeNewswire)
Jan-06-26 04:15PM	Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-25 12:05PM	This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving (Barchart)
07:00AM	Loading…
Dec-15-25 07:00AM	Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis (PR Newswire)
Nov-25-25 04:15PM	Anaptys Announces Participation in December Investor Conferences (GlobeNewswire)
Nov-21-25 04:47PM	AnaptysBio Reverses Higher After Trading Legal Barbs With Pharma Giant GSK (Investor's Business Daily) +5.18% +5.91%
06:14AM	GSK, AnaptysBio Sue Each Other Over Cancer Drug License (The Wall Street Journal)
04:00AM	Anaptys Announces $100 Million Stock Repurchase Plan (GlobeNewswire)
03:50AM	Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary (GlobeNewswire)
Nov-12-25 05:20AM	Metagenomi, Ovid CEOs step aside; Cogent soars on unprecedented stomach cancer data (BioPharma Dive)
Nov-10-25 11:25AM	Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run (Investor's Business Daily) -14.30%
09:00AM	Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis (GlobeNewswire)
Nov-04-25 05:50PM	AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:15PM	Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
04:15PM	Anaptys Announces Participation in November Investor Conferences (GlobeNewswire)
Oct-29-25 10:00AM	Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
09:15AM	Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation (GlobeNewswire)
Oct-28-25 10:00AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
09:15AM	Loading…
Oct-13-25 09:15AM	Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 (GlobeNewswire)
Sep-29-25 04:05PM	Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14 (GlobeNewswire) +31.59%
04:05PM	Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 (GlobeNewswire)
Aug-27-25 04:15PM	Anaptys Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-06-25 05:25PM	AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -9.63%
04:15PM	Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-25 10:00AM	AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jun-03-25 04:05PM	Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA (GlobeNewswire) +7.59% -9.57%
May-27-25 04:15PM	Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 (GlobeNewswire)
May-12-25 03:53PM	AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in Now (Insider Monkey)
May-05-25 05:45PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:15PM	Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-17-25 07:00AM	Bright Peak Therapeutics Appoints John Schmid to its Board of Directors (GlobeNewswire) +7.82%
Mar-25-25 09:21AM	AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last? (Zacks)
Mar-24-25 09:15AM	Anaptys Announces Stock Repurchase Plan (GlobeNewswire) +9.54%
Mar-16-25 06:05AM	Wells Fargo Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Feb-27-25 06:55PM	AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:15PM	Anaptys Announces Participation in March Investor Conferences (GlobeNewswire)
04:15PM	Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-13-25 10:00AM	Truist says AnaptysBio handing of placebo raise doubt about Phase 2 RA data (TipRanks) +19.44%
09:40AM	Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year? (Zacks)
05:11AM	AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains? (Zacks)
Feb-12-25 12:22PM	AnaptysBio achieves highest ever results in Phase II rheumatoid arthritis trial (Clinical Trials Arena) +30.51%
09:23AM	AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment (Investor's Business Daily)
07:30AM	Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months (GlobeNewswire)
Feb-11-25 05:30PM	Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025 (GlobeNewswire)
Feb-04-25 06:37AM	Vanda and AnaptysBio link for generalised pustular psoriasis therapy (Pharmaceutical Technology)
Feb-03-25 04:15PM	Anaptys to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire) -7.08%
07:30AM	Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist (PR Newswire)
Jan-27-25 09:40AM	Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? (Zacks)
Jan-13-25 09:42AM	How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry (Zacks)
Jan-12-25 03:00AM	Big Biotech Fund Loads Up on a Stock That Surged in 2024, and a Loser (Barrons.com)
Jan-07-25 09:15AM	Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-24 05:23AM	AnaptysBios atopic dermatitis trial of BTLA agonist misses endpoints (Clinical Trials Arena)
Dec-11-24 02:07PM	AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data (Benzinga) -32.83%
08:30AM	Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis (GlobeNewswire)
Nov-25-24 09:40AM	Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? (Zacks) +8.22%
Nov-08-24 12:00PM	AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:35AM	Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB) (Zacks)
Nov-05-24 05:30PM	AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +11.72%
04:15PM	Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:15PM	Anaptys Announces Participation in November and December Investor Conferences (GlobeNewswire)
Aug-29-24 09:15AM	Anaptys Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-23-24 07:26AM	Why AnaptysBio Was Such a Healthy Stock This Week (Motley Fool)
Aug-14-24 04:11PM	AnaptysBio Surges After Sanofi Takes A Stake In $100 Million Offering (Investor's Business Daily) -6.35%
10:05AM	AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering (Investor's Business Daily)
05:00AM	Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering (GlobeNewswire)
Aug-05-24 09:54PM	ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
05:55PM	AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-24 10:00AM	AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jul-22-24 02:53PM	AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst (Benzinga) +5.96%
May-09-24 05:45PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -10.75%
04:15PM	Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:10PM	Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) (GlobeNewswire)
04:05PM	Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties (GlobeNewswire)
May-02-24 10:01AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
May-01-24 04:51AM	AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock? (Zacks) +6.90%
Apr-24-24 09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Apr-15-24 02:19PM	BTIG Research Predicts Over 118% Rally for These 3 Stocks (InvestorPlace) -6.34%
Apr-12-24 07:00PM	Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week (Motley Fool) -8.17%
Apr-09-24 02:40PM	Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock. (Zacks)
Mar-14-24 12:00PM	What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to Trade (Zacks)
Mar-11-24 05:30PM	AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.85% +11.61%
04:15PM	Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-29-24 09:15AM	Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting (GlobeNewswire)
Feb-28-24 10:00AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-22-24 04:00AM	13 Best Short Squeeze Stocks To Buy Now (Insider Monkey)
Feb-19-24 05:54AM	Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength? (Zacks)

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schmid John P.	Director	Mar 30 '26	Sale	56.11	20,645	1,158,451	31,622	Apr 01 09:28 PM
JOHN SCHMID	Director	Mar 30 '26	Proposed Sale	56.11	20,645	1,158,451		Mar 30 05:28 PM
Faga Daniel	President, CEO	Mar 27 '26	Sale	61.61	17,679	1,089,199	495,965	Mar 27 08:15 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Feb 11 '26	Option Exercise	29.70	10,000	297,000	22,835	Feb 13 04:05 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Feb 11 '26	Sale	54.00	10,000	540,000	12,835	Feb 13 04:05 PM
ERIC J LOUMEAU	Officer	Feb 11 '26	Proposed Sale	54.00	10,000	540,000		Feb 11 04:36 PM
Marquet Magda	Director	Jan 15 '26	Option Exercise	26.11	11,000	287,210	20,930	Jan 16 01:05 PM
Marquet Magda	Director	Jan 15 '26	Sale	48.23	11,000	530,531	9,930	Jan 16 01:05 PM
MAGDA MARQUET	Director	Jan 15 '26	Proposed Sale	48.23	11,000	530,531		Jan 15 04:06 PM
Lizzul Paul F.	Chief Medical Officer	Jan 08 '26	Sale	44.71	3,650	163,192	42,088	Jan 09 07:16 PM
Paul F. Lizzul	Officer	Jan 08 '26	Proposed Sale	45.21	3,650	165,016		Jan 09 07:15 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Jan 08 '26	Sale	44.71	2,515	112,446	21,852	Jan 09 07:14 PM
DENNIS MULROY	Officer	Jan 08 '26	Proposed Sale	45.21	2,515	113,703		Jan 09 07:14 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Jan 08 '26	Sale	44.71	2,210	98,809	12,835	Jan 09 07:13 PM
ERIC J LOUMEAU	Officer	Jan 08 '26	Proposed Sale	45.21	2,210	99,914		Jan 09 07:12 PM
Faga Daniel	President, CEO	Jan 08 '26	Sale	44.71	14,281	638,504	479,344	Jan 09 07:12 PM
Daniel Faga	Officer	Jan 08 '26	Proposed Sale	45.21	14,281	645,644		Jan 09 07:11 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Jan 07 '26	Sale	45.56	9,639	439,200	9,157	Jan 08 04:12 PM
ERIC J LOUMEAU	Officer	Jan 07 '26	Proposed Sale	43.91	2,017	88,566		Jan 08 04:12 PM
Lizzul Paul F.	Chief Medical Officer	Jan 07 '26	Sale	45.11	2,235	100,821	37,213	Jan 08 04:11 PM
Paul F. Lizzul	Officer	Jan 07 '26	Proposed Sale	43.91	2,235	98,139		Jan 08 04:10 PM
Faga Daniel	President, CEO	Jan 07 '26	Sale	45.11	9,202	415,102	466,787	Jan 08 04:10 PM
Daniel Faga	Officer	Jan 07 '26	Proposed Sale	43.91	9,202	404,060		Jan 08 04:09 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Jan 07 '26	Sale	45.11	1,908	86,070	17,667	Jan 08 04:08 PM
DENNIS MULROY	Officer	Jan 07 '26	Proposed Sale	43.91	1,908	83,780		Jan 08 04:08 PM
ERIC J LOUMEAU	Officer	Jan 07 '26	Proposed Sale	45.69	7,622	348,213		Jan 07 04:06 PM
Faga Daniel	President, CEO	Jan 05 '26	Sale	43.26	15,309	662,267	458,139	Jan 06 09:07 PM
Daniel Faga	Officer	Jan 05 '26	Proposed Sale	44.95	15,309	688,140		Jan 06 09:07 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Jan 05 '26	Sale	43.26	3,363	145,483	14,330	Jan 06 09:05 PM
DENNIS MULROY	Officer	Jan 05 '26	Proposed Sale	44.95	3,363	151,167		Jan 06 09:05 PM
Lizzul Paul F.	Chief Medical Officer	Jan 05 '26	Sale	43.26	4,219	182,514	33,303	Jan 06 09:04 PM
Paul F. Lizzul	Officer	Jan 05 '26	Proposed Sale	44.95	4,219	189,644		Jan 06 09:04 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Jan 05 '26	Sale	43.26	2,983	129,045	13,251	Jan 06 09:03 PM
ERIC J LOUMEAU	Officer	Jan 05 '26	Proposed Sale	44.95	2,983	134,086		Jan 06 09:02 PM
Ware J. Anthony	Director	Dec 23 '25	Sale	49.58	3,900	193,342	9,630	Dec 23 04:30 PM
Lizzul Paul F.	Chief Medical Officer	Dec 22 '25	Option Exercise	18.50	1,500	27,750	28,467	Dec 23 04:28 PM
Lizzul Paul F.	Chief Medical Officer	Dec 22 '25	Sale	50.00	1,500	75,000	26,967	Dec 23 04:28 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Dec 22 '25	Option Exercise	20.16	10,000	201,600	19,401	Dec 23 04:28 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Dec 22 '25	Sale	50.00	10,000	500,000	9,401	Dec 23 04:28 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 22 '25	Option Exercise	14.02	10,000	140,200	18,947	Dec 23 04:27 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 22 '25	Sale	51.00	10,000	510,000	8,947	Dec 23 04:27 PM
JOE ANTHONY WARE	Director	Dec 23 '25	Proposed Sale	49.58	3,900	193,342		Dec 23 04:03 PM
ERIC J LOUMEAU	Officer	Dec 22 '25	Proposed Sale	51.00	10,000	510,000		Dec 22 04:05 PM
PAUL F LIZZUL	Officer	Dec 22 '25	Proposed Sale	50.00	1,500	75,000		Dec 22 04:04 PM
DENNIS MULROY	Officer	Dec 22 '25	Proposed Sale	50.00	10,000	500,000		Dec 22 04:01 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 16 '25	Option Exercise	17.70	12,500	221,300	21,588	Dec 18 04:14 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 17 '25	Option Exercise	14.02	10,000	140,200	19,088	Dec 18 04:14 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 16 '25	Sale	44.86	12,500	560,800	9,088	Dec 18 04:14 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 17 '25	Sale	46.00	10,000	460,000	9,088	Dec 18 04:14 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Dec 18 '25	Sale	46.99	141	6,626	8,947	Dec 18 04:14 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Dec 16 '25	Option Exercise	20.16	10,000	201,600	25,126	Dec 18 04:13 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Dec 16 '25	Sale	44.85	15,725	705,333	9,401	Dec 18 04:13 PM
ERIC J LOUMEAU	Officer	Dec 18 '25	Proposed Sale	46.99	141	6,626		Dec 18 04:11 PM
ERIC J LOUMEAU	Officer	Dec 17 '25	Proposed Sale	46.00	10,000	460,000		Dec 17 04:12 PM
DENNIS MULROY	Officer	Dec 16 '25	Proposed Sale	44.85	15,725	705,333		Dec 16 04:58 PM
ERIC J LOUMEAU	Officer	Dec 16 '25	Proposed Sale	44.86	12,500	560,800		Dec 16 04:09 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 30 '25	Option Exercise	14.02	5,000	70,100	17,328	Oct 01 04:00 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 30 '25	Sale	29.00	8,240	238,960	9,088	Oct 01 04:00 PM
ERIC J LOUMEAU	Officer	Sep 30 '25	Proposed Sale	29.00	8,240	238,960		Sep 30 04:13 PM
Orwin John A	Director	Sep 15 '25	Option Exercise	0.00	1,300	0	10,665	Sep 17 04:02 PM
RENTON HOLLINGS	Director	Aug 08 '25	Option Exercise	6.93	10,231	70,901	15,196	Aug 12 04:02 PM
RENTON HOLLINGS	Director	Aug 08 '25	Sale	19.62	10,231	200,714	4,965	Aug 12 04:02 PM
HOLLINGS C RENTON	Director	Aug 08 '25	Proposed Sale	19.62	10,231	200,713		Aug 08 05:10 PM
RENTON HOLLINGS	Director	Jul 02 '25	Option Exercise	6.93	20,925	145,010	25,890	Jul 03 01:34 PM
RENTON HOLLINGS	Director	Jul 02 '25	Sale	23.57	20,925	493,191	4,965	Jul 03 01:34 PM
HOLLINGS C RENTON	Director	Jul 02 '25	Proposed Sale	23.57	20,925	493,190		Jul 02 04:13 PM
FENTON DENNIS M	Director	Jun 18 '25	Sale	23.97	3,015	72,270	4,965	Jun 20 04:07 PM
RENTON HOLLINGS	Director	Jun 18 '25	Sale	23.97	3,015	72,270	4,965	Jun 20 04:06 PM
HOLLINGS C RENTON	Director	Jun 18 '25	Proposed Sale	23.97	3,015	72,270		Jun 18 04:26 PM
DENNIS M FENTON	Director	Jun 18 '25	Proposed Sale	23.97	3,015	72,270		Jun 18 04:06 PM
Jain Rita	Director	Jun 15 '25	Option Exercise	0.00	7,330	0	11,864	Jun 17 06:33 PM
FENTON DENNIS M	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	7,980	Jun 17 06:33 PM
Marquet Magda	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	9,930	Jun 17 06:32 PM
Orwin John A	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	9,365	Jun 17 06:31 PM
RENTON HOLLINGS	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	7,980	Jun 17 06:30 PM
Schmid John P.	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	52,267	Jun 17 06:30 PM
Ware J. Anthony	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	13,530	Jun 17 06:29 PM

Open in Screener

XERS

Xeris Biopharma Holdings Inc

Apr 01 • 04:00PM ET

6.04

+0.24 4.14 %

Healthcare • Biotechnology • USA • NASD

XERS Xeris Biopharma Holdings Inc daily Stock Chart

Peers: LGND ALKS BCRX SUPN AMRN ANIP MNKD RDHL ECOR

| Held by: VTI IWM VXF IWO XPH SCHA VTWO VHT IHE FESM

Index	RUT	P/E	-	EPS (ttm)	-0.01	Insider Own	7.16%	Shs Outstand	166.22M	Perf Week	13.96%
Market Cap	1.04B	Forward P/E	17.19	EPS next Y	0.35	Insider Trans	-2.43%	Shs Float	160.09M	Perf Month	1.68%
Enterprise Value	1.19B	PEG	-	EPS next Q	0.00	Inst Own	58.76%	Short Float	10.13%	Perf Quarter	-17.37%
Income	0.55M	P/S	3.57	EPS this Y	3641.81%	Inst Trans	2.25%	Short Ratio	7.98	Perf Half Y	-25.80%
Sales	291.85M	P/B	73.34	EPS next Y	192.86%	ROA	0.15%	Short Interest	16.22M	Perf YTD	-23.06%
Book/sh	0.08	P/C	9.38	EPS next 5Y	-	ROE	-	52W High	10.08 -40.08%	Perf Year	18.90%
Cash/sh	0.64	P/FCF	37.29	EPS past 3/5Y	- -	ROIC	0.21%	52W Low	3.81 58.74%	Perf 3Y	270.55%
Dividend Est.	-	EV/EBITDA	31.62	Sales past 3/5Y	38.33% 70.20%	Gross Margin	81.70%	Volatility	5.24% 4.58%	Perf 5Y	33.92%
Dividend TTM	-	EV/Sales	4.07	EPS Y/Y TTM	99.47%	Oper. Margin	8.53%	ATR (14)	0.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.57	Sales Y/Y TTM	43.72%	Profit Margin	0.19%	RSI (14)	54.09	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	2.19	EPS Q/Q	279.30%	SMA20	7.76%	Beta	0.74	Target Price	11.14
Payout	0.00%	Debt/Eq	18.85	Sales Q/Q	42.78%	SMA50	-5.66%	Rel Volume	1.14	Prev Close	5.80
Employees	435	LT Debt/Eq	18.40	Earnings	Mar 02 BMO	SMA200	-12.81%	Avg Volume	2.03M	Price	6.04
IPO	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	191.26% 4.39%	Trades		Volume	2,311,782	Change	4.14%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$9
Aug-12-25	Resumed	H.C. Wainwright	Buy	$10
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral	$3
Mar-28-24	Initiated	Oppenheimer	Outperform	$5
Aug-28-23	Initiated	Craig Hallum	Buy	$4.50
Oct-21-22	Initiated	Jefferies	Buy	$4
Apr-28-22	Initiated	Craig Hallum	Buy	$6.50
Nov-17-21	Initiated	SVB Leerink	Outperform	$6
Oct-29-21	Initiated	H.C. Wainwright	Buy	$4
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$11
Feb-18-20	Initiated	Piper Sandler	Overweight	$12
Jul-16-18	Initiated	RBC Capital Mkts	Outperform	$24
Jul-16-18	Initiated	Leerink Partners	Outperform	$24
Jul-16-18	Initiated	Jefferies	Buy	$23

Show Previous Ratings

Mar-02-26 04:01PM	Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
12:33PM	Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary (Moby)
10:37AM	Xeris Biopharma Q4 Earnings Call Highlights (MarketBeat)
09:30AM	Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:06AM	Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:13AM	Loading…
07:13AM	Xeris Biopharma: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance (Business Wire)
Feb-27-26 12:29PM	Why Are Shares Of Xeris Biopharma Falling Friday? (Benzinga) -9.20%
Feb-26-26 05:55PM	Xeris Biopharma Subsidiaries File Recorlev Patent Infringement Lawsuit (Business Wire)
12:15PM	BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates (Zacks)
09:15AM	Unlocking Q4 Potential of Xeris Biopharma (XERS): Exploring Wall Street Estimates for Key Metrics (Zacks)
05:35AM	TheStreet Pro: Four Stocks that Will Win Despite Irrational Panic over AI (TipRanks)
Feb-17-26 07:30AM	Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026 (Business Wire)
Jan-08-26 07:00AM	Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue (Business Wire) +12.76%
Jan-02-26 04:15PM	Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -6.37%
07:09PM	Loading…
Dec-31-25 07:09PM	Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday (Motley Fool) +7.39%
Dec-18-25 01:13PM	Xeris Biopharma Holdings, Inc. (XERS): A Bull Case Theory (Insider Monkey)
Dec-01-25 07:00AM	Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application (Business Wire)
Nov-06-25 09:30AM	Xeris Biopharma (XERS) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks) -21.88%
08:30AM	Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3 (Zacks)
07:00AM	Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 (Business Wire)
Oct-30-25 06:45PM	Plus Therapeutics (PSTV) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Oct-23-25 07:30AM	Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
Oct-20-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Xeris Biopharma (XERS) is a Great Choice (Zacks)
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? (Zacks)
Oct-16-25 09:06AM	Xeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains? (Zacks)
Oct-13-25 07:58AM	Beat the Market the Zacks Way: MariMed, Xeris Biopharma, Lam Research in Focus (Zacks)
Oct-03-25 04:15PM	Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:00PM	Xeris Biopharma (XERS) is a Great Momentum Stock: Should You Buy? (Zacks)
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)
12:00PM	Loading…
Sep-09-25 12:00PM	What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now? (Zacks)
Aug-29-25 05:09AM	Xeris Biopharma Holdings, Inc. (XERS) Reports Record $71.5M Q2 Revenue (Insider Monkey)
Aug-25-25 07:00AM	Xeris Announces Orange Book Listing of U.S. Patent for Recorlev (Business Wire)
Aug-12-25 12:00PM	Xeris Biopharma (XERS) Upgraded to Buy: Here's Why (Zacks)
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +20.22%
09:30AM	Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:35AM	Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:32AM	Xeris Biopharma: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance (Business Wire)
Jul-31-25 07:30AM	Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-03-25 08:19AM	Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last? (Zacks)
Jun-03-25 07:30AM	Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day (Business Wire) -7.92%
May-20-25 07:30AM	Xeris Announces Details for Analyst & Investor Day (Business Wire)
May-12-25 03:54PM	Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now (Insider Monkey)
May-09-25 03:21AM	Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-08-25 08:20AM	Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +15.18%
07:17AM	Xeris Biopharma: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Record First Quarter 2025 Financial Results (Business Wire)
May-07-25 12:08PM	Xeris Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
11:51AM	Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings (Seeking Alpha)
May-05-25 05:30PM	Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates (Zacks) -7.33%
May-01-25 07:00AM	Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire)
Apr-22-25 06:46PM	Is Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires? (Insider Monkey)
Apr-17-25 07:00AM	Bright Peak Therapeutics Appoints John Schmid to its Board of Directors (GlobeNewswire)
Mar-28-25 08:00AM	Xeris Announces Changes to Its Board of Directors (Business Wire)
Mar-27-25 10:18AM	Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-20-25 10:13AM	Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Mar-19-25 04:49PM	Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game (InsiderMonkey) +5.56%
Mar-17-25 08:00AM	Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx (glucagon) for Use as a Diagnostic Aid (Business Wire)
Mar-07-25 02:08AM	Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... (GuruFocus.com)
Mar-06-25 09:30AM	Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings (Zacks) +9.55%
08:15AM	Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:22AM	Xeris Biopharma: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance (Business Wire)
Feb-27-25 07:00AM	Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 (Business Wire)
Feb-26-25 10:00AM	Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-24-25 08:00AM	Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer (Business Wire)
Feb-05-25 08:00AM	Xeris to Participate in Upcoming Investor Conferences (Business Wire)
Jan-21-25 09:00AM	The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness (PR Newswire)
Jan-11-25 07:27AM	Xeris Biopharma raises FY24 revenue view to $203M from $198M-$202M (TipRanks)
Jan-10-25 07:00AM	Xeris Expects to Exceed Full-Year 2024 Financial Guidance (Business Wire)
Jan-06-25 04:15PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.37%
Nov-26-24 07:00AM	Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-09-24 02:06AM	Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Nov-08-24 09:30AM	Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:10AM	Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Xeris Biopharma: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-31-24 08:00AM	Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024 (Business Wire)
Oct-04-24 04:05PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Aug-22-24 07:00AM	Xeris to Participate in Upcoming Investor Conferences (Business Wire)
Aug-08-24 08:25AM	Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Xeris Biopharma: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-01-24 10:01AM	Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-25-24 07:00AM	Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire) +6.02%
Jul-24-24 09:55AM	Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy? (Zacks) -5.12%
Jul-08-24 07:00AM	Xeris Biopharma Announces CEO Succession Plan (Business Wire)
Jul-03-24 01:05PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jun-03-24 07:00AM	Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev) in Cushings Syndrome Patients at ENDO 2024 (Business Wire) +8.65%
May-30-24 07:30AM	Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121) (Business Wire) +15.03%
07:00AM	Xeris to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-10-24 03:21PM	Xeris Biopharma Holdings Inc (XERS) Q1 2024 Earnings: Revenue Growth Amidst Challenges (GuruFocus.com) -6.38%
12:36PM	Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:27AM	Q1 2024 Xeris Biopharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-24 11:55AM	XERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:10AM	Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:11AM	Xeris Biopharma: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events (Business Wire)

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brady James Aloysius	Director	Mar 30 '26	Sale	5.54	10,834	60,036	89,166	Apr 01 05:54 PM
JAMES BRADY	Director	Mar 30 '26	Proposed Sale	5.40	10,834	58,504		Mar 30 05:31 PM
McCulloch Kevin	See Remarks	Mar 12 '26	Option Exercise	4.09	48,898	199,992	1,777,725	Mar 16 06:11 PM
Pieper Steven	See Remarks	Mar 05 '26	Option Exercise	4.71	41,927	197,308	1,408,940	Mar 05 07:18 PM
Hecht Beth	See Remarks	Mar 02 '26	Sale	6.25	16,667	104,086	1,226,507	Mar 04 05:28 PM
BETH HECHT	Officer	Mar 02 '26	Proposed Sale	6.12	66,668	408,008		Mar 02 04:36 PM
Hecht Beth	See Remarks	Feb 02 '26	Sale	7.45	16,667	124,147	1,243,174	Feb 02 06:11 PM
McCulloch Kevin	See Remarks	Jan 08 '26	Sale	8.00	15,000	120,000	1,685,426	Jan 09 05:34 PM
KEVIN MCCULLOCH	Officer	Jan 08 '26	Proposed Sale	7.21	60,000	432,600		Jan 08 04:22 PM
Shannon John Patrick Jr	See Remarks	Jan 05 '26	Option Exercise	1.63	92,301	149,998	2,797,647	Jan 06 06:14 PM
Shannon John Patrick Jr	See Remarks	Jan 05 '26	Sale	7.08	24,907	176,257	2,705,346	Jan 06 06:14 PM
Hecht Beth	See Remarks	Jan 02 '26	Sale	7.43	16,667	123,776	1,308,103	Jan 05 06:01 PM
JOHN H JOHNSON	Director	Dec 19 '25	Proposed Sale	7.22	135,402	977,034		Dec 19 06:15 PM
JOHNSON JOHN	Director	Dec 19 '25	Sale	7.22	135,400	977,019	698,083	Dec 19 05:17 PM
BORMANN-KENNEDY BARBARA-JEAN A	Director	Dec 12 '25	Sale	7.09	15,000	106,414	142,500	Dec 15 05:24 PM
BARBARA-JEAN A BORMANN-KENNEDY	Director	Dec 12 '25	Proposed Sale	7.01	15,000	105,150		Dec 12 04:20 PM
Hecht Beth	See Remarks	Dec 01 '25	Sale	7.01	16,667	116,781	1,320,176	Dec 02 05:14 PM
Shannon John Patrick Jr	See Remarks	Nov 14 '25	Option Exercise	1.55	87,100	135,005	2,730,253	Nov 17 05:58 PM
Shannon John Patrick Jr	See Remarks	Nov 13 '25	Option Exercise	1.55	8,970	13,904	2,666,395	Nov 17 05:58 PM
Shannon John Patrick Jr	See Remarks	Nov 13 '25	Sale	7.46	23,242	173,402	2,643,153	Nov 17 05:58 PM
Hecht Beth	See Remarks	Nov 11 '25	Sale	7.40	16,667	123,296	1,336,843	Nov 13 06:59 PM
JOHN SHANNON	Director	Nov 13 '25	Proposed Sale	7.59	48,149	365,451		Nov 13 04:25 PM
BETH HECHT	Officer	Nov 11 '25	Proposed Sale	7.72	66,668	514,677		Nov 12 07:02 AM
PERSKY MARLA	Director	Sep 11 '25	Sale	7.72	15,500	119,610	142,000	Sep 12 05:09 PM
MARLA PERSKY	Director	Sep 11 '25	Proposed Sale	7.81	15,500	121,055		Sep 11 04:24 PM
SHERMAN JEFFREY W	Director	Aug 28 '25	Option Exercise	6.66	47,040	313,286	261,420	Aug 29 05:21 PM
SHERMAN JEFFREY W	Director	Aug 28 '25	Sale	7.92	42,232	334,515	219,188	Aug 29 05:21 PM
JEFFREY SHERMAN	Director	Aug 28 '25	Proposed Sale	7.92	42,232	334,511		Aug 28 04:09 PM
JOHNSON JOHN	Director	Aug 13 '25	Sale	7.32	107,500	786,459	833,483	Aug 15 04:57 PM
HALKUFF DAWN	Director	Aug 12 '25	Sale	7.28	42,500	309,226	115,000	Aug 13 04:47 PM
JOHN H JOHNSON	Director	Aug 13 '25	Proposed Sale	7.32	107,500	786,452		Aug 13 04:08 PM
DAWN HALKUFF	Director	Aug 12 '25	Proposed Sale	7.28	42,500	309,226		Aug 12 04:23 PM
McCulloch Kevin	See Remarks	Jun 13 '25	Buy	4.38	25,000	109,475	1,708,585	Jun 16 04:26 PM
Fairley Ricki Louise	Director	May 09 '25	Proposed Sale	4.90	56,667	277,668		May 09 05:28 PM

ANAB

AnaptysBio Inc

XERS

Xeris Biopharma Holdings Inc

Upgrade your Finviz experience